Articles From: Alimera Sciences Announces $37.5 Million Private Placement to ALK's partner in North America, Merck, presents data on investigational house dust mite sublingual allergy immunotherapy tablet


2014/1/28
ATLANTA , Jan.
Sign-up for Alimera Sciences Announces $37.5 Million Private Placement investment picks
2014/3/27
ATLANTA , March 27, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN ® to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date.
Sign-up for Alimera Sciences Announces Resubmission Of ILUVIEN® New Drug Application To FDA investment picks
2014/2/3
ATLANTA , Feb.
Sign-up for Alimera Sciences Closes $37.5 Million Private Placement investment picks
2013/10/18
Alimera Continues Focus on European Growth ATLANTA , Oct.
Sign-up for Alimera Sciences Receives Complete Response Letter For ILUVIEN® investment picks
2014/2/27
ILUVIEN® Revenue Growth in Europe Continues $37.5 Million Private Placement Completed to Expand ILUVIEN Commercialization Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA , Feb.
Sign-up for Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results investment picks
Company Generates First Revenue from ILUVIEN® Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA , Aug.
Sign-up for Alimera Sciences Reports Second Quarter 2013 Financial Results investment picks
2013/11/11
ILUVIEN Revenue Increases 323% from Second Quarter of 2013 Alimera Prepares for FDA Advisory Committee Meeting Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA , Nov.
Sign-up for Alimera Sciences Reports Third Quarter 2013 Financial Results investment picks
2014/1/13
First NHS patient treated less than seven weeks following NICE published guidance ATLANTA , Jan.
Sign-up for Alimera Sciences Ships First ILUVIEN® Orders For U.K. National Health Service Hospitals investment picks
2014/2/13
ATLANTA , Feb.
Sign-up for Alimera Sciences To Present At Citi 2014 Global Healthcare Conference investment picks
2014/2/28
ATLANTA , Feb.
Sign-up for Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference investment picks
2014/2/20
ATLANTA , Feb.
Sign-up for Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results investment picks
2013/8/5
ATLANTA , Aug.
Sign-up for Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results investment picks
2014/3/19
BARCELONA, Spain and ATLANTA, March 19, 2014 (GLOBE NEWSWIRE) -- Alimerka, a leading Spanish food grocery retailer, has selected multiple components from Manhattan Associates ' (Nasdaq:MANH) Supply Chain Commerce Solutions portfolio to enable new supply chain processes and maximize service levels across the 176 supermarket stores it operates in the Asturias, Castilla-León and Galicia regions of Northern Spain.
Sign-up for Alimerka Selects Manhattan Supply Chain Commerce Solutions to Strengthen Brand Loyalty and Enable Business Growth investment picks
2014/1/13
http://media.marketwire.com/attachments/200711/383726_AliosBioPharmalogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1081077&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Alios BioPharma Reports Significant Progress With Its Clinical Program for AL-8176, Its Nucleoside Analog for the Treatment of Respiratory Syncytial Virus (RSV) investment picks
2014/2/24
http://media.marketwire.com/attachments/201310/67151_SGI_Logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1092205&ProfileId=051205&sourceType=1 MILPITAS, CA --
Sign-up for Alison Ryan, Americas Sales Vice President of SGI Recognized as One of CRN's 2014 Channel Chiefs investment picks
WEX Inc. (NYSE: WEX), a leading provider of corporate payment solutions, today announced Alison Vanderhoof has joined the company as senior vice president, general manager for emerging markets.
Sign-up for Alison Vanderhoof Joins WEX as SVP, General Manager for Emerging Markets investment picks
2013/10/11
ROME--Alitalia's board voted Friday in favor of a new proposal to raise 300 million euros ($405 million) from the struggling airline's shareholders in the latest move to avoid bankruptcy.
Sign-up for Alitalia Board Approves $405 Million Capital Increase investment picks
2014/1/13
By Christopher Emsden ROME--Alitalia Chief Executive Gabriele Del Torchio said Monday the troubled airline may need to raise yet more capital even after its just-completed EUR300 million capital increase.
Sign-up for Alitalia CEO Says He's Optimistic About Etihad Talks -- Update investment picks
By Laura Bonadies and Gilles Castonguay MILAN--Alitalia shareholder Fondiaria-SAI SpA (FSA.MI) won't take part in a EUR300 million capital increase intended to save the Italian airline from insolvency, the head of the insurer's parent company said Friday.
Sign-up for Alitalia Investor Fondiaria-SAI to Skip Capital Increase investment picks
2013/10/15
MILAN--Alitalia's (ATL.MI) shareholders have approved a proposal to raise up to 300 million euros ($406.9 million) in new funding in an effort to save the troubled Italian airline from bankruptcy.
Sign-up for Alitalia Shareholders Agree to Raise Funds investment picks
By Gilles Castonguay MILAN--Alitalia's (ATL.MI) shareholders have approved a proposal to raise up to 300 million euros ($406.9 million) in new funding in an effort to save the troubled Italian airline from bankruptcy.
Sign-up for Alitalia Shareholders Agree to Raise Funds; Board to Resign investment picks
2013/10/15
By Gilles Castonguay MILAN--Alitalia's shareholders have agreed to revise downward to 50 million euros ($67.8 million) the value of the beleaguered airline, according to a person familiar with the matter.
Sign-up for Alitalia Shareholders Agreed EUR50 Million as Equity Value - Source investment picks
2014/2/18
Alitalia's shareholders Tuesday approved a change in the Italian airline's statutes to help Etihad Airways avoid the risk of having to buy the entire airline after making an initial investment in it.
Sign-up for Alitalia Shareholders Change Statute to Help Etihad investment picks
2013/8/2
NEW YORK, Aug.
Sign-up for AlixPartners to Provide Integration Support in Standard Register's Acquisition of WorkflowOne investment picks
2013/12/26
COPENHAGEN, Dec.
Sign-up for ALK announces FDA Advisory Committee to review ragweed sublingual AIT tablet investment picks
2014/1/24
COPENHAGEN, Denmark, Jan.
Sign-up for ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet investment picks
By Dominic Chopping STOCKHOLM--Danish pharmaceutical company ALK-Abello A/S (ALK-B.KO) Friday reported lower net profit in the third quarter compared with the same period a year ago.
Sign-up for ALK-Abello Cuts Fiscal Year Guidance On Deferred Milestone Payment investment picks
2014/3/4
COPENHAGEN, Denmark, March 4, 2014 (GLOBE NEWSWIRE) -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK's partner in North America, Merck (NYSE:MRK) , known as MSD outside the USA and Canada, presents new data from a Phase IIb trial with its investigational sublingual house dust mite allergy immunotherapy tablet at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego, USA.
Sign-up for ALK's partner in North America, Merck, presents data on investigational house dust mite sublingual allergy immunotherapy tablet investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Alimera Sciences Announces $37.5 Million Private Placement to ALK's partner in North America, Merck, presents data on investigational house dust mite sublingual allergy immunotherapy tablet
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity